<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:02:17Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10502520" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10502520</identifier>
        <datestamp>2023-09-16</datestamp>
        <setSpec>jamasd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id>
              <journal-title-group>
                <journal-title>JAMA Network Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2574-3805</issn>
              <publisher>
                <publisher-name>American Medical Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10502520</article-id>
              <article-id pub-id-type="pmcid">PMC10502520</article-id>
              <article-id pub-id-type="pmc-uid">10502520</article-id>
              <article-id pub-id-type="pmid">37707817</article-id>
              <article-id pub-id-type="pmid">37707817</article-id>
              <article-id pub-id-type="doi">10.1001/jamanetworkopen.2023.31284</article-id>
              <article-id pub-id-type="publisher-id">zoi230908</article-id>
              <article-categories>
                <subj-group subj-group-type="category" specific-use="electronic">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Investigation</subject>
                </subj-group>
                <subj-group subj-group-type="online-only">
                  <subject>Online Only</subject>
                </subj-group>
                <subj-group subj-group-type="subject-area">
                  <subject>Cardiology</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Temporal Association Among Influenza-Like Illness, Cardiovascular Events, and Vaccine Dose in Patients With High-Risk Cardiovascular Disease</article-title>
                <subtitle>Secondary Analysis of a Randomized Clinical Trial</subtitle>
                <alt-title alt-title-type="headline">Influenza-Like Illness, CV Events, and Vaccine Dose in CV Disease</alt-title>
                <alt-title alt-title-type="running-head">Influenza-Like Illness, CV Events, and Vaccine Dose in CV Disease</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hegde</surname>
                    <given-names>Sheila M.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MPH</degrees>
                  <xref rid="zoi230908aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Claggett</surname>
                    <given-names>Brian L.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230908aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Udell</surname>
                    <given-names>Jacob A.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MPH</degrees>
                  <xref rid="zoi230908aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kim</surname>
                    <given-names>KyungMann</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230908aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Joseph</surname>
                    <given-names>Jacob</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi230908aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Farkouh</surname>
                    <given-names>Michael E.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MSc</degrees>
                  <xref rid="zoi230908aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Peikert</surname>
                    <given-names>Alexander</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi230908aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bhatt</surname>
                    <given-names>Ankeet S.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MBA</degrees>
                  <xref rid="zoi230908aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tattersall</surname>
                    <given-names>Matthew C.</given-names>
                  </name>
                  <degrees>DO</degrees>
                  <degrees>MS</degrees>
                  <xref rid="zoi230908aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bhatt</surname>
                    <given-names>Deepak L.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MPH</degrees>
                  <xref rid="zoi230908aff7" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cooper</surname>
                    <given-names>Lawton S.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MPH</degrees>
                  <xref rid="zoi230908aff8" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Solomon</surname>
                    <given-names>Scott D.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi230908aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Vardeny</surname>
                    <given-names>Orly</given-names>
                  </name>
                  <degrees>PharmD</degrees>
                  <degrees>MS</degrees>
                  <xref rid="zoi230908aff9" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                  <xref rid="zoi230908aff10" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="zoi230908aff1"><label>1</label>Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts</aff>
              <aff id="zoi230908aff2"><label>2</label>Women’s College Hospital and Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada</aff>
              <aff id="zoi230908aff3"><label>3</label>Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison</aff>
              <aff id="zoi230908aff4"><label>4</label>Brown University, The Warren Alpert Medical School, Providence, Rhode Island</aff>
              <aff id="zoi230908aff5"><label>5</label>Kaiser Permanente Division of Research, Northern California, Oakland</aff>
              <aff id="zoi230908aff6"><label>6</label>Department of Medicine, University of Wisconsin-Madison</aff>
              <aff id="zoi230908aff7"><label>7</label>Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, Mount Sinai Health System, New York, New York</aff>
              <aff id="zoi230908aff8"><label>8</label>National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, Maryland</aff>
              <aff id="zoi230908aff9"><label>9</label>Department of Medicine, University of Minnesota, Minneapolis</aff>
              <aff id="zoi230908aff10"><label>10</label>VA Minneapolis Health Care System, US Department of Veterans Affairs, Minneapolis, Minnesota</aff>
              <author-notes>
                <title>Article Information</title>
                <p><bold>Accepted for Publication:</bold> July 22, 2023.</p>
                <p content-type="published-online"><bold>Published:</bold> September 14, 2023. <?xpp bx;1?>doi:<uri content-type="doi">10.1001/jamanetworkopen.2023.31284</uri></p>
                <p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. © 2023 Hegde SM et al. <italic>JAMA Network Open</italic>.</p>
                <corresp id="zoi230908cor1"><bold>Corresponding Author:</bold> Orly Vardeny, PharmD, MS, VA Minneapolis Health Care System, US Department of Veterans Affairs, 1 Veterans Dr, Minneapolis, MN 55417 (<email xlink:href="ovardeny@umn.edu">ovardeny@umn.edu</email>).</corresp>
                <p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Hegde and Claggett had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p>
                <p><italic>Concept and design:</italic> Hegde, Udell, Kim, Joseph, Farkouh, A. S. Bhatt, Tattersall, D. L. Bhatt, Solomon, Vardeny.</p>
                <p><italic>Acquisition, analysis, or interpretation of data:</italic> Hegde, Claggett, Udell, Kim, Joseph, Peikert, Tattersall, D. L. Bhatt, Cooper, Vardeny.</p>
                <p><italic>Drafting of the manuscript:</italic> Hegde, Vardeny.</p>
                <p><italic>Critical review of the manuscript for important intellectual content:</italic> All authors.</p>
                <p><italic>Statistical analysis:</italic> Hegde, Claggett, Kim.</p>
                <p><italic>Obtained funding:</italic> Kim, Solomon.</p>
                <p><italic>Administrative, technical, or material support:</italic> Hegde, Kim, Tattersall.</p>
                <p><italic>Supervision:</italic> Claggett, Kim, Joseph, Tattersall, Solomon, Vardeny.</p>
                <p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Hegde reported receiving funding from Bristol Myers Squibb (BMS) to the Brigham and Women’s Hospital for core echocardiographic laboratory services outside the submitted work. Dr Udell reported receiving grants from AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, and Sanofi and receiving personal fees from GlaxoSmithKline and Novartis outside the submitted work. Dr Joseph reported receiving grants from the National Heart, Lung, and Blood Institute for research during the conduct of the study and receiving grants from Amgen, Kowa, and Alnylam outside the submitted work. Dr Farkouh reported receiving grants from Novartis and Novo Nordisk, funding from the AstraZeneca Data and Safety Monitoring Board service, and personal fees from Otitopic outside the submitted work. Dr Peikert reported receiving grants from the German Research Foundation outside the submitted work. Dr A. S. Bhatt reported receiving personal fees from Sanofi outside the submitted work. Dr D. L. Bhatt reported serving on the advisory boards of Angiowave, Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, PracticeUpdate Cardiology for Elsevier, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, and Stasys; on the boards of directors of Angiowave (with stock options), Boston VA Research Institute, BMS (with stock options), DRS.LINQ (with stock options), High Enroll (with stock options), the Society of Cardiovascular Patient Care, and TobeSoft; as the inaugural chair of the American Heart Association (AHA) Quality Oversight Committee; as a consultant of Broadview Ventures and Hims; on the Data Monitoring Committee of Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute) for the PORTICO trial funded by St Jude Medical (now Abbott), Boston Scientific (chair) for the PEITHO trial, Cleveland Clinic (including for the ExCEED trial) funded by Edwards, Contego Medical (chair) for the PERFORMANCE 2 trial, Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine for the ENVISAGE trial funded by Daiichi Sankyo and for the ABILITY-DM trial funded by Concept Medical, Novartis, Population Health Research Institute, and Rutgers University for the National Institutes of Health–funded MINT trial; as chair of the American College of Cardiology Accreditation Oversight Committee, the Arnold and Porter law firm (work related to Sanofi/BMS clopidogrel litigation), and the Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute); on the Clinical Trial Steering Committee of the RE-DUAL PCI trial funded by Boehringer Ingelheim, the Canadian Medical and Surgical Knowledge Translation Research Group, and the Duke Clinical Research Institute (including for the PRONOUNCE trial funded by Ferring Pharmaceuticals); on the AEGIS-II Executive Committee funded by CSL Behring; as editor in chief of the <italic>Harvard Heart Letter</italic> for Belvoir Publications and of the <italic>Journal of Invasive Cardiology</italic> for HMP Global; as a guest editor and associate editor of the <italic>Journal of the American College of Cardiology</italic>; as cochair of K2P for interdisciplinary curriculum; on the Continuing Medical Education Steering Committee of Medtelligence/ReachMD and WebMD; as course director of the Comprehensive Review of Interventional Cardiology for Oakstone continuing medical education; on the Operations, Publications, and Steering Committees of the Population Health Research Institute for the COMPASS trial; as a USA national coleader funded by Bayer; as chief medical editor of <italic>Cardiology Today’s Intervention</italic> for Slack Publications; as secretary/treasurer of the Society of Cardiovascular Patient Care; on the Steering Committee of Wiley; as deputy editor of <italic>Clinical Cardiology</italic>; on the Registry Steering Committee (chair) of the National Cardiovascular Data Registry ACTION; on the Research and Publications Committee (chair) of the Veterans Affairs Clinical Assessment Reporting and Tracking; as a site coinvestigator of Abbott, Biotronik, Boston Scientific, Central States Industrial, Endotronix, St Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, and Vascular Solutions; and as a trustee of the American College of Cardiology; performing unfunded research for FlowCo and Takeda; receiving honoraria from the American College of Cardiology as senior associate editor of the Clinical Trials and News website and ACC.org; speaker honorarium for an AHA lecture for CSL Behring; research funding from Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, BMS, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Eli Lilly &amp; Company, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, and 89Bio; royalties from Elsevier as editor of <italic>Braunwald’s Heart Disease</italic>; and having a patent with sotagliflozin assigned to Brigham and Women’s Hospital assigned to Lexicon with no income received; and consulting for Cowen and Company, MJH Life Sciences, Piper Sandler. Dr Solomon reported receiving grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Eli Lilly &amp; Company, Mesoblast, MyoKardia, NIH/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and Us2.ai grants to the Brigham and Women’s Hospital and personal fees from Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi Sankyo, GSK, Eli Lilly &amp; Company, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, and Valo for consulting outside the submitted work. Dr Vardeny reported receiving personal fees from Sanofi-Pasteur outside the submitted work. No other disclosures were reported.</p>
                <p content-type="funding-statement"><bold>Funding/Support:</bold> This study was supported by grants U01HL130163 and U01HL130204 from the NHLBI (Drs Kim, Solomon, and Vardeny). Additional funding was provided by Sanofi Pasteur (Dr Solomon).</p>
                <p><bold>Role of the Funder/Sponsor:</bold> Sanofi Pasteur had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p>
                <p><bold>Disclaimer:</bold> The views expressed in this article are those of the authors and do not necessarily represent the views of the US government, the NHLBI, the NIH, or the US Department of Health and Human Services.</p>
                <p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZOI230908-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p>
                <p><bold>Additional Information:</bold> Dr Cooper is retired from the NHLBI, NIH. Vaccines were provided by Sanofi Pasteur.</p>
              </author-notes>
              <pub-date pub-type="epub" iso-8601-date="2023-09-14T10:00">
                <day>14</day>
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>14</day>
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>6</volume>
              <issue>9</issue>
              <elocation-id>e2331284</elocation-id>
              <history>
                <date date-type="received">
                  <day>17</day>
                  <month>4</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>22</day>
                  <month>7</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright 2023 Hegde SM et al. <italic>JAMA Network Open</italic>.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf-version" xlink:href="jamanetwopen-e2331284.pdf">jamanetwopen-e2331284.pdf</self-uri>
              <self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.31284"/>
              <abstract abstract-type="teaser" specific-use="electronic">
                <p>This secondary analysis of the INVESTED randomized clinical trial assesses whether high-dose compared with standard-dose influenza vaccine was temporally associated with cardiovascular (CV) events among patients with high-risk CV disease during periods of high influenza-like illness activity.</p>
              </abstract>
              <abstract abstract-type="key-points">
                <title>Key Points</title>
                <sec id="ab-zoi230908-1">
                  <title>Question</title>
                  <p>Does high-dose compared with standard-dose influenza vaccine reduce cardiopulmonary events during periods of high, local influenza activity?</p>
                </sec>
                <sec id="ab-zoi230908-2">
                  <title>Findings</title>
                  <p>In this secondary analysis of the INVESTED randomized clinical trial of 3094 participants from US sites with available weekly Centers for Disease Control and Prevention–reported influenza-like illness (ILI) activity, ILI was temporally associated with cardiopulmonary and cardiovascular (CV) hospitalizations. However, high-dose compared with standard-dose influenza vaccine did not significantly reduce occurrence of the primary outcome.</p>
                </sec>
                <sec id="ab-zoi230908-3">
                  <title>Meaning</title>
                  <p>The findings indicate that influenza activity was temporally associated with CV events in patients with high-risk CV disease, and temporal CV risk was not significantly reduced by a higher influenza vaccine dose.</p>
                </sec>
              </abstract>
              <abstract>
                <sec id="ab-zoi230908-4">
                  <title>Importance</title>
                  <p>Influenza-like illness (ILI) activity has been associated with increased risk of cardiopulmonary (CP) events during the influenza season. High-dose trivalent influenza vaccine was not superior to standard-dose quadrivalent vaccine for reducing these events in patients with high-risk cardiovascular (CV) disease in the Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED) trial.</p>
                </sec>
                <sec id="ab-zoi230908-5">
                  <title>Objective</title>
                  <p>To evaluate whether high-dose trivalent influenza vaccination is associated with benefit over standard-dose quadrivalent vaccination in reducing CP events during periods of high, local influenza activity.</p>
                </sec>
                <sec id="ab-zoi230908-6">
                  <title>Design, Setting, and Participants</title>
                  <p>This study was a prespecified secondary analysis of INVESTED, a multicenter, double-blind, active comparator randomized clinical trial conducted over 3 consecutive influenza seasons from September 2016 to July 2019. Follow-up was completed in July 2019, and data were analyzed from September 21, 2016, to July 31, 2019. Weekly Centers for Disease Control and Prevention (CDC)–reported, state-level ILI activity was ascertained to assess the weekly odds of the primary outcome. The study population included 3094 patients with high-risk CV disease from participating centers in the US.</p>
                </sec>
                <sec id="ab-zoi230908-7">
                  <title>Intervention</title>
                  <p>Participants were randomized to high-dose trivalent or standard-dose quadrivalent influenza vaccine and revaccinated for up to 3 seasons.</p>
                </sec>
                <sec id="ab-zoi230908-8">
                  <title>Main Outcomes and Measures</title>
                  <p>The primary outcome was the time to composite of all-cause death or CP hospitalization within each season. Additional measures included weekly CDC-reported ILI activity data by state.</p>
                </sec>
                <sec id="ab-zoi230908-9">
                  <title>Results</title>
                  <p>Among 3094 participants (mean [SD] age, 65 [12] years; 2309 male [75%]), we analyzed 129 285 person-weeks of enrollment, including 1396 composite primary outcome events (1278 CP hospitalization, 118 deaths). A 1% ILI increase in the prior week was associated with an increased risk in the primary outcome (odds ratio [OR], 1.14; 95% CI, 1.07-1.21; <italic>P</italic> &lt; .001), CP hospitalization (OR, 1.13; 95% CI, 1.06-1.21; <italic>P</italic> &lt; .001), and CV hospitalization (OR, 1.12; 95% CI, 1.04-1.19; <italic>P</italic> = .001), after adjusting for state, demographic characteristics, enrollment strata, and CV risk factors. Increased ILI activity was not associated with all-cause death (OR, 1.00; 95% CI, 0.88-1.13; <italic>P</italic> &gt; .99). High-dose compared with standard-dose vaccine did not significantly reduce the primary outcome, even when the analysis was restricted to weeks of high ILI activity (OR, 0.88; 95% CI, 0.65-1.20; <italic>P</italic> = .43). Traditionally warmer months in the US were associated with lower CV risk independent of local ILI activity.</p>
                </sec>
                <sec id="ab-zoi230908-10">
                  <title>Conclusions and Relevance</title>
                  <p>In this secondary analysis of a randomized clinical trial, ILI activity was temporally associated with increased CP events in patients with high-risk CV disease, and a higher influenza vaccine dose did not significantly reduce temporal CV risk. Other seasonal factors may play a role in the coincident high rates of ILI and CV events.</p>
                </sec>
                <sec id="ab-zoi230908-11">
                  <title>Trial Registration</title>
                  <p>ClinicalTrials.gov Identifier: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT02787044?term=NCT02787044&amp;rank=1" ext-link-type="uri">NCT02787044</ext-link></p>
                </sec>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec id="H1-1-ZOI230908">
              <title>Introduction</title>
              <p>Influenza has been associated with increased risk of cardiopulmonary (CP) events, including myocardial infarction (MI) and heart failure (HF).<sup><xref rid="zoi230908r1" ref-type="bibr">1</xref>,<xref rid="zoi230908r2" ref-type="bibr">2</xref>,<xref rid="zoi230908r3" ref-type="bibr">3</xref>,<xref rid="zoi230908r4" ref-type="bibr">4</xref>,<xref rid="zoi230908r5" ref-type="bibr">5</xref>,<xref rid="zoi230908r6" ref-type="bibr">6</xref>,<xref rid="zoi230908r7" ref-type="bibr">7</xref>,<xref rid="zoi230908r8" ref-type="bibr">8</xref></sup> Proposed mechanisms that suggest an association between influenza infection and cardiovascular (CV) risk include induction of systemic effects via immune stimulation and inflammation that can provoke plaque rupture, increased metabolic demand, adrenergic surge, hypoxia, hypercoagulability, and direct myocardial toxic effects.<sup><xref rid="zoi230908r9" ref-type="bibr">9</xref>,<xref rid="zoi230908r10" ref-type="bibr">10</xref></sup> Seasonal outbreaks of influenza occur primarily in winter months when transmission may be more favorable, and CV events demonstrate a similar temporal pattern.<sup><xref rid="zoi230908r11" ref-type="bibr">11</xref></sup> Time-series analyses have also demonstrated an association between influenza and CV events in observational and retrospective studies.<sup><xref rid="zoi230908r12" ref-type="bibr">12</xref>,<xref rid="zoi230908r13" ref-type="bibr">13</xref></sup> Influenza vaccine may be involved in reducing adverse CV outcomes, as suggested by observational and randomized clinical trials.<sup><xref rid="zoi230908r14" ref-type="bibr">14</xref>,<xref rid="zoi230908r15" ref-type="bibr">15</xref>,<xref rid="zoi230908r16" ref-type="bibr">16</xref>,<xref rid="zoi230908r17" ref-type="bibr">17</xref>,<xref rid="zoi230908r18" ref-type="bibr">18</xref>,<xref rid="zoi230908r19" ref-type="bibr">19</xref></sup></p>
              <p>The Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED) trial assessed the efficacy of high-dose trivalent or standard-dose quadrivalent influenza vaccine in North American participants with high-risk CV disease during the 2016 to 2019 influenza seasons.<sup><xref rid="zoi230908r20" ref-type="bibr">20</xref></sup> The primary end point was time to first CP hospitalization or all-cause death in each season. High-dose vaccine was not superior to standard-dose vaccine for the primary end point, which assessed benefit from 2 weeks following vaccination through the end of July of each influenza season.<sup><xref rid="zoi230908r21" ref-type="bibr">21</xref></sup> Whether treatment efficacy may be different during periods of high influenza-like illness (ILI) activity is not known. In this analysis, we compared locally defined ILI activity, as provided by the Centers for Disease Control and Prevention (CDC), with outcomes in INVESTED and assessed whether high-dose compared with standard-dose influenza vaccine modified the events in association with locally determined ILI activity.</p>
            </sec>
            <sec id="H1-2-ZOI230908">
              <title>Methods</title>
              <p>This secondary analysis of a randomized clinical trial was a prespecified analysis of the INVESTED trial, a pragmatic, randomized, double-blind, active comparator trial conducted at 157 participating centers in the US and Canada from September 2016 to July 2019. Follow-up was completed in July 2019. Patients with high-risk CV disease previously hospitalized for either MI in the past 12 months or HF in the past 24 months were randomized to high-dose or standard-dose influenza vaccine. The protocol and primary results have been previously published (<xref rid="note-ZOI230908-1-s" ref-type="supplementary-material">Supplement 1</xref> and <xref rid="zoi230908f1" ref-type="fig">Figure 1</xref>).<sup><xref rid="zoi230908r21" ref-type="bibr">21</xref></sup> This study was a preplanned analysis of the parent trial and follows the Consolidated Standards of Reporting Trials (<ext-link xlink:href="https://www.equator-network.org/reporting-guidelines/consort/" ext-link-type="uri">CONSORT</ext-link>) reporting guideline for randomized studies.<sup><xref rid="zoi230908r22" ref-type="bibr">22</xref></sup> Ethics committees at each enrolling site approved the protocol or the review was ceded to a central institutional review board. All participants provided written informed consent in accordance with established guidelines.</p>
              <fig position="float" id="zoi230908f1" fig-type="figure">
                <label>Figure 1. </label>
                <caption>
                  <title>CONSORT Diagram</title>
                  <p>The number of patients screened was not collected.</p>
                </caption>
                <graphic xlink:href="jamanetwopen-e2331284-g001" position="float"/>
              </fig>
              <sec id="H2-1-ZOI230908">
                <title>Association Between ILI and CV Events</title>
                <p>Influenza-like illness was defined based on the percentage of visits to sentinel clinicians for fever (temperature ≥37.8 °C) and a cough and/or a sore throat without a known cause other than influenza as reported to the CDC US Outpatient Influenza-Like Illness Surveillance Network. Therefore, ILI could have included any respiratory pathogen presenting with these symptoms. We included CDC data from 108 US sites and territories; sites from Florida and Canada were not included due to unavailable weekly ILI data. Race categories included Asian, Black, First Nations or American Indian, White, and other (Native Hawaiian, Pacific Islander, &gt;1 race, chooses not to report, does not know, and not available or missing), and ethnicity categories included Hispanic or Latino, non-Hispanic or non-Latino, and other (chooses not to report, does not know, and not available or missing). Race and ethnicity were ascertained by self-report.</p>
              </sec>
              <sec id="H2-2-ZOI230908">
                <title>Statistical Analysis</title>
                <sec id="H3-1-ZOI230908">
                  <title>Primary and Secondary Outcomes</title>
                  <p>Data were analyzed from September 21, 2016, to July 31, 2019. We compared publicly available, weekly, CDC-reported, state-level ILI with the weekly occurrence of the primary outcome (composite of all-cause death or CP hospitalization) and secondary outcomes (death, CV hospitalization, and pulmonary hospitalization) among US participants from September 2016 to July 2019 using logistic regression models. Weekly ILI activity from 0 to 9 weeks prior to (lag 0 to lag 9) the outcome of interest was considered to assess the temporal association between exposure and outcome. Model 1 was adjusted for state, demographics (age, self-reported sex, and race) and enrollment strata (history of MI, history of hospitalization for HF). Model 2 was additionally adjusted for CV risk factors (diabetes, body mass index &gt;30 [calculated as weight in kilograms divided by height in meters squared], kidney impairment, current smoker, peripheral arterial disease, ischemic stroke, hypertension, hyperlipidemia, asthma, chronic obstructive pulmonary disease, percutaneous coronary intervention, coronary artery bypass graft, atrial fibrillation, and implantable cardioverter-defibrillator).</p>
                </sec>
                <sec id="H3-2-ZOI230908">
                  <title>Treatment Outcome</title>
                  <p>To assess the treatment outcome, we used logistic regression models to evaluate the weekly odds of the primary outcome for the high-dose compared with standard-dose vaccine treatment group adjusting for state to account for possible regional differences. In a sensitivity analysis, we analyzed the association between ILI activity and outcomes (1) only during months with typically higher influenza activity (September 15th to May 15th of each enrolling season) and (2) during weeks with higher ILI activity (&gt;2 SDs above a state’s mean ILI activity). Last, we compared weekly ILI with outcomes adjusting for state, vaccine treatment assignment, and month, referenced to the month of July.</p>
                  <p>Analyses were performed using Stata, version 14 (StataCorp LLC), and statistical significance was set at 2-sided <italic>P</italic> &lt; .05. <italic>P</italic> values were not adjusted for multiple testing.</p>
                </sec>
              </sec>
            </sec>
            <sec id="H1-3-ZOI230908">
              <title>Results</title>
              <p>In this sample of 3094 US participants (mean [SD] age, 65 [12] years; 781 [25.2%] were female, 2309 [74.6%] were male, and 4 participants did not report sex [0.1%]). Of these, 30 (1.0%) were Asian, 690 (22.3%) Black, 12 (0.4%) First Nations or American Indian, 226 (7.3%) Hispanic or Latino, 2832 (91.5%) non-Hispanic or non-Latino, 2238 (72.3%) White, 124 (4.0%) other race, and 36 (1.2%) other ethnicity. Baseline characteristics and concomitant therapies were well balanced between treatment groups (<xref rid="zoi230908t1" ref-type="table">Table 1</xref>). The majority of enrolled participants (2352 [76.0%]) had an HF qualifying event, 672 (21.7%) had prior HF hospitalization, and 375 (12.1%) had a prior MI event. The sample associated 129 285 person-weeks of enrollment with 1396 composite primary outcome events (1278 CP hospitalizations, 118 deaths), 322 deaths, 1141 CV hospitalizations, and 183 pulmonary hospitalizations. A lag of 1 week was chosen for the logistic regression analyses relating ILI activity to the primary and secondary outcomes via forward stepwise selection models (eTable in <xref rid="note-ZOI230908-1-s" ref-type="supplementary-material">Supplement 2</xref>). Mean ILI activity over time, as reported by the CDC and risk of the primary outcome over time are shown in <xref rid="zoi230908f2" ref-type="fig">Figure 2</xref>. Mean ILI activity was the highest in the 2017 to 2018 season.</p>
              <table-wrap position="float" id="zoi230908t1">
                <label>Table 1. </label>
                <caption>
                  <title>Baseline Characteristics of Participants in the Sample Compared With Participants in the INVESTED Trial</title>
                </caption>
                <table frame="hsides" rules="groups">
                  <col width="38.53%" span="1"/>
                  <col width="18.27%" span="1"/>
                  <col width="21.84%" span="1"/>
                  <col width="21.36%" span="1"/>
                  <thead>
                    <tr>
                      <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th>
                      <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Sample influenza vaccine, No. (%)</th>
                      <th rowspan="2" valign="top" align="left" scope="col" colspan="1">INVESTED trial, No. (%) (n = 5260)</th>
                    </tr>
                    <tr>
                      <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">High dose (n = 1548)</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Standard dose (n = 1546)</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Randomization y</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2016-2017</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">161 (10.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">162 (10.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">494 (9.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2017-2018</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">761 (49.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">769 (49.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2502 (47.6)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2018-2019</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">626 (40.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">615 (39.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2264 (43.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, mean (SD), y</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">65 (13)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">67 (13)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">66 (13)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">395 (25.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">386 (25.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1473 (28.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1152 (74.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1157 (74.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3773 (71.7)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Race</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Asian</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">12 (0.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">18 (1.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">155 (2.9)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Black</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">336 (21.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">354 (22.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">784 (14.9)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> First Nations or American Indian</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">6 (0.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">6 (0.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">49 (0.9)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> White</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1130 (73.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1108 (71.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4103 (78.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other<xref rid="zoi230908t1n1" ref-type="table-fn"><sup>a</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">64 (4.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">60 (3.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">169 (3.2)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Ethnicity</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hispanic or Latino</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">121 (7.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">105 (6.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">517 (9.8)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Non-Hispanic or non-Latino</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1410 (91.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1422 (92.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4683 (89.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other<xref rid="zoi230908t1n2" ref-type="table-fn"><sup>b</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">17 (1.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">19 (1.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">60 (1.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ejection fraction, mean (SD), %</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">41 (17)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">42 (16)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">42 (16)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">BMI, mean (SD)<xref rid="zoi230908t1n3" ref-type="table-fn"><sup>c</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">31.9 (8.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">31.7 (7.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">30.9 (7.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Qualifying event</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> HF</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1170 (75.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1182 (76.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3289 (62.7)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> MI</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">377 (24.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">361 (23.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1960 (37.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Eligibility risk factor</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Age &gt;65 y</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">854 (55.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">862 (55.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2987 (56.9)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Current BMI &gt;30<xref rid="zoi230908t1n3" ref-type="table-fn"><sup>c</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">823 (53.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">833 (54.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2551 (48.6)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Current or past LVEF &lt;40%</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">758 (49.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">751 (48.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2208 (42.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Type 1 or type 2 diabetes</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">610 (39.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">630 (40.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1950 (37.2)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> History of chronic kidney disease</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">567 (36.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">573 (37.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1587 (30.2)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Current tobacco smoker</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">219 (14.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">261 (16.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">902 (17.2)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Prior HF hospitalization</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">341 (22.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">331 (21.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">903 (17.2)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Prior MI</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">187 (12.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">188 (12.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">745 (14.2)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> History of ischemic stroke</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">138 (8.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">132 (8.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">433 (8.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> History of peripheral artery disease</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">79 (5.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">80 (5.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">232 (4.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Other medical or surgical history</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hypertension</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1250 (80.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1211 (78.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4046 (77.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Dyslipidemia</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1066 (68.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1058 (68.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3616 (68.9)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Percutaneous coronary intervention</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">524 (33.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">529 (34.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2162 (41.2)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Atrial fibrillation</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">591 (38.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">597 (38.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1725 (32.9)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Coronary artery bypass graft</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">308 (19.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">317 (20.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1040 (19.8)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Chronic obstructive pulmonary disease</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">340 (22.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">338 (21.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1006 (19.2)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Implantable cardioverter-defibrillator</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">371 (24.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">368 (23.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">956 (18.2)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Asthma</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">175 (11.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">192 (12.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">602 (11.5)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Canadian Cardiovascular Society grading classification<xref rid="zoi230908t1n4" ref-type="table-fn"><sup>d</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> I</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">179 (54.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">186 (57.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1116 (61.2)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> II</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">98 (29.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">86 (26.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">498 (27.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> III</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">39 (11.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">44 (13.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">142 (7.8)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> IV</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">12 (3.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">7 (2.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">68 (3.7)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">New York Heart Association Functional Classification<xref rid="zoi230908t1n4" ref-type="table-fn"><sup>d</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> I</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">176 (15.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">177 (15.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">543 (17.2)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> II</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">546 (48.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">529 (47.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1584 (50.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> III</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">354 (31.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">377 (33.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">931 (29.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> IV</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">41 (3.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">40 (3.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">104 (3.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Maintenance medications for those with MI as index event</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Statins</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">346 (91.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">329 (91.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1785 (91.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Aspirin</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">335 (88.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">326 (90.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1835 (93.6)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> β–Blocker</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">342 (9.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">316 (87.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1679 (85.7)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Maintenance medications for those with HF as index event</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> β–Blocker</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">988 (84.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">990 (83.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2779 (84.5)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Diuretic</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">970 (82.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">975 (82.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2607 (79.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ACE inhibitor, ARB, or ARN inhibitor</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">765 (65.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">780 (66.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2197 (66.8)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mineralocorticoid receptor antagonist</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">391 (33.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">410 (34.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1118 (34.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Digoxin</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">113 (9.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">101 (8.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">314 (9.6)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <p>Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARN, angiotensin receptor neprilysin; BMI, body mass index; HF, heart failure; INVESTED, Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure; LVEF, left ventricular ejection fraction; MI, myocardial infarction.</p>
                  <fn id="zoi230908t1n1">
                    <label>
                      <sup>a</sup>
                    </label>
                    <p>Other race included Native Hawaiian, Pacific Islander, more than 1 race, chooses not to report, does not know, and not available or missing.</p>
                  </fn>
                  <fn id="zoi230908t1n2">
                    <label>
                      <sup>b</sup>
                    </label>
                    <p>Other ethnicity included chooses to report, does not know, and not available or missing.</p>
                  </fn>
                  <fn id="zoi230908t1n3">
                    <label>
                      <sup>c</sup>
                    </label>
                    <p>Calculated as weight in kilograms divided by height in meters squared.</p>
                  </fn>
                  <fn id="zoi230908t1n4">
                    <label>
                      <sup>d</sup>
                    </label>
                    <p>Limitation classifications: I, none; II, slight; III, moderate; and IV, severe.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <fig position="float" id="zoi230908f2" fig-type="figure">
                <label>Figure 2. </label>
                <caption>
                  <title>Temporal Risk of the Primary Outcome</title>
                  <p>Association between risk of the primary outcome (composite of cardiopulmonary hospitalization or death) per patient-week and mean influenza-like illness (ILI) activity over time.</p>
                </caption>
                <graphic xlink:href="jamanetwopen-e2331284-g002" position="float"/>
              </fig>
              <sec id="H2-3-ZOI230908">
                <title>Association Between ILI Activity and CV Events</title>
                <p>A 1% ILI increase in the prior week was associated with an increased risk in the primary outcome of composite of CP hospitalization or all-cause death (odds ratio [OR], 1.14; 95% CI, 1.07-1.21; <italic>P</italic> &lt; .001), CP hospitalization (OR, 1.13; 95% CI, 1.06-1.21; <italic>P</italic> &lt; .001), and CV hospitalization (OR, 1.12; 95% CI, 1.04-1.19; <italic>P</italic> = .001) after adjusting for state, demographic characteristics, enrollment strata, and CV risk factors (<xref rid="zoi230908t2" ref-type="table">Table 2</xref>). No association was found between increased ILI activity and pulmonary hospitalizations (OR, 1.18; 95% CI, 0.99-1.40; <italic>P</italic> = .06). Increased ILI activity was not associated with all-cause death (OR, 1.00; 95% CI, 0.88-1.13; <italic>P</italic> &gt; .99).</p>
                <table-wrap position="float" id="zoi230908t2">
                  <label>Table 2. </label>
                  <caption>
                    <title>Association of Weekly Odds of Primary and Secondary Outcomes With Influenza-Like Illness Activity<xref rid="zoi230908t2n1" ref-type="table-fn"><sup>a</sup></xref></title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="28.89%" span="1"/>
                    <col width="13.11%" span="1"/>
                    <col width="19.52%" span="1"/>
                    <col width="9.53%" span="1"/>
                    <col width="19.42%" span="1"/>
                    <col width="9.53%" span="1"/>
                    <thead>
                      <tr>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1"/>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Events, No.</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Model 1, OR (95% CI)<xref rid="zoi230908t2n2" ref-type="table-fn"><sup>b</sup></xref></th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> value</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Model 2, OR (95% CI)<xref rid="zoi230908t2n3" ref-type="table-fn"><sup>c</sup></xref></th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Composite primary outcome</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1396</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.14 (1.07-1.22)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.14 (1.07-1.21)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cardiopulmonary hospitalization</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1278</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.14 (1.07-1.21)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.13 (1.06-1.21)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">All-cause death</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">322</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.00 (0.89-1.14)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&gt;.99</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.00 (0.88-1.13)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">&gt;.99</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">CV hospitalization</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1141</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.12 (1.05-1.20)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.001</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.12 (1.04-1.19)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.001</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pulmonary hospitalization</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">183</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.18 (0.99-1.39)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.06</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.18 (0.99-1.40)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.06</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: CV, cardiovascular; OR, odds ratio.</p>
                    <fn id="zoi230908t2n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Patient-weeks of influenza-like illness activity were associated with outcomes with a lag of 1 week.</p>
                    </fn>
                    <fn id="zoi230908t2n2">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Model 1: adjusted for state, age, sex, race, history of myocardial infarction, and history of heart failure.</p>
                    </fn>
                    <fn id="zoi230908t2n3">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>Model 2: adjusted for model 1 and diabetes, body mass index &gt;30 (calculated as weight in kilograms divided by height in meters squared), kidney impairment, current smoker, peripheral arterial disease, ischemic stroke, hypertension, hyperlipidemia, asthma, chronic obstructive pulmonary disease, percutaneous coronary intervention, coronary artery bypass graft, atrial fibrillation, and implantable cardioverter-defibrillator.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Warmer months (July, August, and September) were associated with a lower risk of events even after adjusting for ILI (<xref rid="zoi230908f3" ref-type="fig">Figure 3</xref>). <xref rid="zoi230908f3" ref-type="fig">Figure 3</xref> demonstrates the weekly odds of the primary outcome by month (referenced to July) after adjusting for ILI, vaccine treatment assignment, and state.</p>
                <fig position="float" id="zoi230908f3" fig-type="figure">
                  <label>Figure 3. </label>
                  <caption>
                    <title>Temporal Risk of the Primary Outcome by Month Independent of Influenza-Like Illness Activity</title>
                    <p>Weekly odds of the primary outcome (composite of cardiopulmonary hospitalization or death) by month (referenced to July), after adjusting for influenza-like illness, treatment, and state.</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-e2331284-g003" position="float"/>
                </fig>
              </sec>
              <sec id="H2-4-ZOI230908">
                <title>Treatment Effect</title>
                <p>Evaluation of the weekly odds of the primary outcome by treatment yielded similar results to the primary results from the INVESTED trial. High-dose was not superior to standard-dose vaccine in its association with risk of the primary outcome (CP hospitalization or death) in the prespecified primary analysis after adjusting for state (OR, 1.07; 95% CI, 0.95-1.20; <italic>P</italic> = .25), when restricting analysis to months with typically higher influenza activity (OR, 1.09; 95% CI, 0.97-1.24; <italic>P</italic> = .15), or during weeks of high ILI activity (OR, 0.88; 95% CI, 0.65-1.20; <italic>P</italic> = .43) in this temporal analysis.</p>
              </sec>
            </sec>
            <sec id="H1-4-ZOI230908">
              <title>Discussion</title>
              <p>In this secondary analysis of the INVESTED randomized clinical trial, ILI was temporally associated with CP and CV hospitalization but not with all-cause death in patients with high-risk CV disease. A higher dose of trivalent influenza vaccine compared with standard-dose quadrivalent influenza vaccine did not modify this association, even after restricting the analysis to months with typically higher influenza activity or weeks in which ILI activity was high. Warmer months in the US were associated with lower CV risk independent of local ILI activity.</p>
              <p>The primary end point of INVESTED was designed to capture CP events that occurred during the broad influenza season, but not necessarily during times of high influenza activity, because we hypothesized that if influenza infection led to CV and pulmonary events, the events might occur even several months after a primary infection. Nevertheless, we anticipated the possibility that modification of these events might be more temporally associated with influenza infection. This prespecified analysis was designed to assess whether high-dose influenza vaccine would provide greater benefit than standard-dose vaccine during times of high influenza activity. That we did not observe a benefit in this analysis suggests that in a high-risk population, the higher dose of vaccine was not associated with modification of events that were extremely likely. However, the benefit of any influenza vaccine compared with placebo in this population cannot be determined from this analysis. Based on other data comparing vaccination with placebo, it is likely that influenza vaccination with either dose would have more substantial benefits over placebo in patients with high risk.<sup><xref rid="zoi230908r23" ref-type="bibr">23</xref></sup> Moreover, as the influenza virus is not the only circulating virus during the winter months, it is possible that other respiratory viruses may contribute to the association between time and CV events.</p>
              <p>In patients with high-risk CV disease, ILI activity was temporally associated with CP and CV hospitalizations. Although a similar OR for pulmonary-related hospitalizations was present, there was no association with increased ILI activity, which may in part be attributed to the small number of events (n = 183) and underscores the relatively higher occurrence of CV (n = 1141) compared with pulmonary events in this sample. Furthermore, individual-level ILI or infection was not assessed in this sample, so the true incidence of influenza is not known. Nevertheless, the temporal association with CV events supported prior findings of emergency department visits in New York City of the association of ILI with CV mortality and in observational data in an older cohort of the association of ILI with MI and HF events.<sup><xref rid="zoi230908r12" ref-type="bibr">12</xref>,<xref rid="zoi230908r13" ref-type="bibr">13</xref></sup> This association remained when the analysis focused on months with typically higher influenza activity and weeks with high ILI activity.</p>
              <p>Although all participants received influenza vaccine, the temporal association between ILI activity and CV events remained. Additional analysis demonstrated that warmer months were associated with lower risk of CV events after accounting for ILI activity and vaccine dose, suggesting that other seasonal factors may also play a role in the seasonal variation in CV events. Vaccine effectiveness was not associated with a modification in the seasonality of ILI and CV events in another analysis of New York state data.<sup><xref rid="zoi230908r24" ref-type="bibr">24</xref></sup> Unmeasured environmental factors, such as temperature, absolute and relative humidity, and wind speed, have been associated with influenza outbreaks and CV events with some variation by influenza subtypes and may explain some of the seasonal variation.<sup><xref rid="zoi230908r25" ref-type="bibr">25</xref>,<xref rid="zoi230908r26" ref-type="bibr">26</xref>,<xref rid="zoi230908r27" ref-type="bibr">27</xref>,<xref rid="zoi230908r28" ref-type="bibr">28</xref>,<xref rid="zoi230908r29" ref-type="bibr">29</xref></sup> Registry data from Sweden have similarly demonstrated the impact of seasonal environmental factors, which attenuated the association between higher incidence of MI and higher incidence of influenza.<sup><xref rid="zoi230908r30" ref-type="bibr">30</xref></sup></p>
              <sec id="H2-5-ZOI230908">
                <title>Limitations</title>
                <p>Several limitations of this analysis should be noted. Inferences about the association between patient-level influenza illness or other respiratory viruses and subsequent events could not be made, as the respiratory influenza infection status of participants was not assessed in this study. State-level ILI activity may not have represented regional-level or patient-level ILI activity. Only states with available ILI activity were included in this analysis, which limited generalizability to participants, excluding those in Florida and Canada. That we did not randomize patients to placebo prevented us from drawing conclusions about the impact of any influenza vaccination on the temporal association between ILI activity and CV events. Also, the difference in valence between the high-dose trivalent influenza vaccine and the standard-dose quadrivalent vaccine may have contributed to the absence of outcome modification of the vaccine dose, with the standard-dose vaccine providing additional coverage for the influenza B/Yamagata strain. Changes in seasonal temperature, humidity, weather patterns, and other environmental factors were not accounted for in this analysis. Additionally, the trial had limited power for this prespecified secondary analysis.</p>
              </sec>
            </sec>
            <sec id="H1-5-ZOI230908">
              <title>Conclusions</title>
              <p>In this secondary analysis of the INVESTED randomized clinical trial evaluating the efficacy of high-dose trivalent vaccine compared with standard-dose quadrivalent vaccine in reducing CP events among patients with high-risk CV disease in the US, influenza activity was temporally associated with an increasing risk of CP events, yet a higher-dose influenza vaccine did not significantly reduce temporal CV risk. Other seasonal factors may also play a role in the higher rate of CV events associated with high rates of influenza. Further studies and additional measures are needed to understand additional factors influencing the temporal association between influenza and CV events and to assess new strategies to reduce events.</p>
            </sec>
          </body>
          <back>
            <ref-list id="REF-ZOI230908">
              <title>References</title>
              <ref id="zoi230908r1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Barnes</surname><given-names>M</given-names></string-name>, <string-name><surname>Heywood</surname><given-names>AE</given-names></string-name>, <string-name><surname>Mahimbo</surname><given-names>A</given-names></string-name>, <string-name><surname>Rahman</surname><given-names>B</given-names></string-name>, <string-name><surname>Newall</surname><given-names>AT</given-names></string-name>, <string-name><surname>Macintyre</surname><given-names>CR</given-names></string-name></person-group>. <article-title>Acute myocardial infarction and influenza: a meta-analysis of case-control studies</article-title>. <source>Heart</source>. <year>2015</year>;<volume>101</volume>(<issue>21</issue>):<fpage>1738</fpage>-<lpage>1747</lpage>. doi:<pub-id pub-id-type="doi">10.1136/heartjnl-2015-307691</pub-id><?supplied-pmid 26310262?><pub-id pub-id-type="pmid">26310262</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Sandoval</surname><given-names>C</given-names></string-name>, <string-name><surname>Walter</surname><given-names>SD</given-names></string-name>, <string-name><surname>Krueger</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>Risk of hospitalization during influenza season among a cohort of patients with congestive heart failure</article-title>. <source>Epidemiol Infect</source>. <year>2007</year>;<volume>135</volume>(<issue>4</issue>):<fpage>574</fpage>-<lpage>582</lpage>. doi:<pub-id pub-id-type="doi">10.1017/S095026880600714X</pub-id><?supplied-pmid 16938140?><pub-id pub-id-type="pmid">16938140</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Smeeth</surname><given-names>L</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>SL</given-names></string-name>, <string-name><surname>Hall</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Hubbard</surname><given-names>R</given-names></string-name>, <string-name><surname>Farrington</surname><given-names>P</given-names></string-name>, <string-name><surname>Vallance</surname><given-names>P</given-names></string-name></person-group>. <article-title>Risk of myocardial infarction and stroke after acute infection or vaccination</article-title>. <source>N Engl J Med</source>. <year>2004</year>;<volume>351</volume>(<issue>25</issue>):<fpage>2611</fpage>-<lpage>2618</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa041747</pub-id><?supplied-pmid 15602021?><pub-id pub-id-type="pmid">15602021</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Warren-Gash</surname><given-names>C</given-names></string-name>, <string-name><surname>Smeeth</surname><given-names>L</given-names></string-name>, <string-name><surname>Hayward</surname><given-names>AC</given-names></string-name></person-group>. <article-title>Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review</article-title>. <source>Lancet Infect Dis</source>. <year>2009</year>;<volume>9</volume>(<issue>10</issue>):<fpage>601</fpage>-<lpage>610</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(09)70233-6</pub-id><?supplied-pmid 19778762?><pub-id pub-id-type="pmid">19778762</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Corrales-Medina</surname><given-names>VF</given-names></string-name>, <string-name><surname>Alvarez</surname><given-names>KN</given-names></string-name>, <string-name><surname>Weissfeld</surname><given-names>LA</given-names></string-name>, <etal/></person-group>. <article-title>Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease</article-title>. <source>JAMA</source>. <year>2015</year>;<volume>313</volume>(<issue>3</issue>):<fpage>264</fpage>-<lpage>274</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2014.18229</pub-id><?supplied-pmid 25602997?><pub-id pub-id-type="pmid">25602997</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kulick</surname><given-names>ER</given-names></string-name>, <string-name><surname>Alvord</surname><given-names>T</given-names></string-name>, <string-name><surname>Canning</surname><given-names>M</given-names></string-name>, <string-name><surname>Elkind</surname><given-names>MSV</given-names></string-name>, <string-name><surname>Chang</surname><given-names>BP</given-names></string-name>, <string-name><surname>Boehme</surname><given-names>AK</given-names></string-name></person-group>. <article-title>Risk of stroke and myocardial infarction after influenza-like illness in New York state</article-title>. <source>BMC Public Health</source>. <year>2021</year>;<volume>21</volume>(<issue>1</issue>):<fpage>864</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12889-021-10916-4</pub-id><?supplied-pmid 33952233?><pub-id pub-id-type="pmid">33952233</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Panhwar</surname><given-names>MS</given-names></string-name>, <string-name><surname>Kalra</surname><given-names>A</given-names></string-name>, <string-name><surname>Gupta</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Effect of influenza on outcomes in patients with heart failure</article-title>. <source>JACC Heart Fail</source>. <year>2019</year>;<volume>7</volume>(<issue>2</issue>):<fpage>112</fpage>-<lpage>117</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jchf.2018.10.011</pub-id><?supplied-pmid 30611718?><pub-id pub-id-type="pmid">30611718</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Tripathi</surname><given-names>B</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>V</given-names></string-name>, <string-name><surname>Kalra</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Influence of influenza infection on in-hospital acute myocardial infarction outcomes</article-title>. <source>Am J Cardiol</source>. <year>2020</year>;<volume>130</volume>:<fpage>7</fpage>-<lpage>14</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.amjcard.2020.05.045</pub-id><?supplied-pmid 32636019?><pub-id pub-id-type="pmid">32636019</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Udell</surname><given-names>JA</given-names></string-name>, <string-name><surname>Farkouh</surname><given-names>ME</given-names></string-name>, <string-name><surname>Solomon</surname><given-names>SD</given-names></string-name>, <string-name><surname>Vardeny</surname><given-names>O</given-names></string-name></person-group>. <article-title>Does influenza vaccination influence cardiovascular complications?</article-title><source>Expert Rev Cardiovasc Ther</source>. <year>2015</year>;<volume>13</volume>(<issue>6</issue>):<fpage>593</fpage>-<lpage>596</lpage>. doi:<pub-id pub-id-type="doi">10.1586/14779072.2015.1044439</pub-id><?supplied-pmid 25971953?><pub-id pub-id-type="pmid">25971953</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Vardeny</surname><given-names>O</given-names></string-name>, <string-name><surname>Solomon</surname><given-names>SD</given-names></string-name></person-group>. <article-title>Influenza vaccination: a one-shot deal to reduce cardiovascular events</article-title>. <source>Eur Heart J</source>. <year>2017</year>;<volume>38</volume>(<issue>5</issue>):<fpage>334</fpage>-<lpage>337</lpage>. <?supplied-pmid 27856498?><pub-id pub-id-type="pmid">27856498</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Lane</surname><given-names>MA</given-names></string-name>, <string-name><surname>Walawender</surname><given-names>M</given-names></string-name>, <string-name><surname>Brownsword</surname><given-names>EA</given-names></string-name>, <etal/></person-group>. <article-title>The impact of cold weather on respiratory morbidity at Emory Healthcare in Atlanta</article-title>. <source>Sci Total Environ</source>. <year>2022</year>;<volume>813</volume>:<elocation-id>152612</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.scitotenv.2021.152612</pub-id><?supplied-pmid 34963597?><pub-id pub-id-type="pmid">34963597</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kytömaa</surname><given-names>S</given-names></string-name>, <string-name><surname>Hegde</surname><given-names>S</given-names></string-name>, <string-name><surname>Claggett</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>Association of influenza-like illness activity with hospitalizations for heart failure: the Atherosclerosis Risk in Communities study</article-title>. <source>JAMA Cardiol</source>. <year>2019</year>;<volume>4</volume>(<issue>4</issue>):<fpage>363</fpage>-<lpage>369</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamacardio.2019.0549</pub-id><?supplied-pmid 30916717?><pub-id pub-id-type="pmid">30916717</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Nguyen</surname><given-names>JL</given-names></string-name>, <string-name><surname>Yang</surname><given-names>W</given-names></string-name>, <string-name><surname>Ito</surname><given-names>K</given-names></string-name>, <string-name><surname>Matte</surname><given-names>TD</given-names></string-name>, <string-name><surname>Shaman</surname><given-names>J</given-names></string-name>, <string-name><surname>Kinney</surname><given-names>PL</given-names></string-name></person-group>. <article-title>Seasonal influenza infections and cardiovascular disease mortality</article-title>. <source>JAMA Cardiol</source>. <year>2016</year>;<volume>1</volume>(<issue>3</issue>):<fpage>274</fpage>-<lpage>281</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamacardio.2016.0433</pub-id><?supplied-pmid 27438105?><pub-id pub-id-type="pmid">27438105</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Udell</surname><given-names>JA</given-names></string-name>, <string-name><surname>Zawi</surname><given-names>R</given-names></string-name>, <string-name><surname>Bhatt</surname><given-names>DL</given-names></string-name>, <etal/></person-group>. <article-title>Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis</article-title>. <source>JAMA</source>. <year>2013</year>;<volume>310</volume>(<issue>16</issue>):<fpage>1711</fpage>-<lpage>1720</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2013.279206</pub-id><?supplied-pmid 24150467?><pub-id pub-id-type="pmid">24150467</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Mohseni</surname><given-names>H</given-names></string-name>, <string-name><surname>Kiran</surname><given-names>A</given-names></string-name>, <string-name><surname>Khorshidi</surname><given-names>R</given-names></string-name>, <string-name><surname>Rahimi</surname><given-names>K</given-names></string-name></person-group>. <article-title>Influenza vaccination and risk of hospitalization in patients with heart failure: a self-controlled case series study</article-title>. <source>Eur Heart J</source>. <year>2017</year>;<volume>38</volume>(<issue>5</issue>):<fpage>326</fpage>-<lpage>333</lpage>. <?supplied-pmid 27660378?><pub-id pub-id-type="pmid">27660378</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Modin</surname><given-names>D</given-names></string-name>, <string-name><surname>Claggett</surname><given-names>B</given-names></string-name>, <string-name><surname>Køber</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Influenza vaccination is associated with reduced cardiovascular mortality in adults with diabetes: a nationwide cohort study</article-title>. <source>Diabetes Care</source>. <year>2020</year>;<volume>43</volume>(<issue>9</issue>):<fpage>2226</fpage>-<lpage>2233</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc20-0229</pub-id><?supplied-pmid 32647052?><pub-id pub-id-type="pmid">32647052</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Rodrigues</surname><given-names>BS</given-names></string-name>, <string-name><surname>Alves</surname><given-names>M</given-names></string-name>, <string-name><surname>Duarte</surname><given-names>GS</given-names></string-name>, <string-name><surname>Costa</surname><given-names>J</given-names></string-name>, <string-name><surname>Pinto</surname><given-names>FJ</given-names></string-name>, <string-name><surname>Caldeira</surname><given-names>D</given-names></string-name></person-group>. <article-title>The impact of influenza vaccination in patients with cardiovascular disease: an overview of systematic reviews</article-title>. <source>Trends Cardiovasc Med</source>. <year>2021</year>;<volume>31</volume>(<issue>5</issue>):<fpage>315</fpage>-<lpage>320</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tcm.2020.06.003</pub-id><?supplied-pmid 32535214?><pub-id pub-id-type="pmid">32535214</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Fröbert</surname><given-names>O</given-names></string-name>, <string-name><surname>Götberg</surname><given-names>M</given-names></string-name>, <string-name><surname>Erlinge</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial</article-title>. <source>Circulation</source>. <year>2021</year>;<volume>144</volume>(<issue>18</issue>):<fpage>1476</fpage>-<lpage>1484</lpage>. doi:<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.121.057042</pub-id><?supplied-pmid 34459211?><pub-id pub-id-type="pmid">34459211</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Behrouzi</surname><given-names>B</given-names></string-name>, <string-name><surname>Bhatt</surname><given-names>DL</given-names></string-name>, <string-name><surname>Cannon</surname><given-names>CP</given-names></string-name>, <etal/></person-group>. <article-title>Association of influenza vaccination with cardiovascular risk: a meta-analysis</article-title>. <source>JAMA Netw Open</source>. <year>2022</year>;<volume>5</volume>(<issue>4</issue>):<elocation-id>e228873</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.8873</pub-id><?supplied-pmid 35486404?><pub-id pub-id-type="pmid">35486404</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Vardeny</surname><given-names>O</given-names></string-name>, <string-name><surname>Udell</surname><given-names>JA</given-names></string-name>, <string-name><surname>Joseph</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: rationale and design of the INVESTED trial</article-title>. <source>Am Heart J</source>. <year>2018</year>;<volume>202</volume>:<fpage>97</fpage>-<lpage>103</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ahj.2018.05.007</pub-id><?supplied-pmid 29909156?><pub-id pub-id-type="pmid">29909156</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Vardeny</surname><given-names>O</given-names></string-name>, <string-name><surname>Kim</surname><given-names>K</given-names></string-name>, <string-name><surname>Udell</surname><given-names>JA</given-names></string-name>, <etal/>; <collab>INVESTED Committees and Investigators</collab></person-group>. <article-title>Effect of high-dose trivalent vs standard-dose quadrivalent influenza vaccine on mortality or cardiopulmonary hospitalization in patients with high-risk cardiovascular disease: a randomized clinical trial</article-title>. <source>JAMA</source>. <year>2021</year>;<volume>325</volume>(<issue>1</issue>):<fpage>39</fpage>-<lpage>49</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2020.23649</pub-id><?supplied-pmid 33275134?><pub-id pub-id-type="pmid">33275134</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Schulz</surname><given-names>KF</given-names></string-name>, <string-name><surname>Altman</surname><given-names>DG</given-names></string-name>, <string-name><surname>Moher</surname><given-names>D</given-names></string-name>, <string-name><surname>Group</surname><given-names>C</given-names></string-name>; <collab>CONSORT Group</collab></person-group>. <article-title>CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials</article-title>. <source>BMJ</source>. <year>2010</year>;<volume>340</volume>:<fpage>c332</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.c332</pub-id><?supplied-pmid 20332509?><pub-id pub-id-type="pmid">20332509</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Loeb</surname><given-names>M</given-names></string-name>, <string-name><surname>Roy</surname><given-names>A</given-names></string-name>, <string-name><surname>Dokainish</surname><given-names>H</given-names></string-name>, <etal/>; <collab>Influenza Vaccine to Prevent Adverse Vascular Events investigators</collab></person-group>. <article-title>Influenza vaccine to reduce adverse vascular events in patients with heart failure: a multinational randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet Glob Health</source>. <year>2022</year>;<volume>10</volume>(<issue>12</issue>):<fpage>e1835</fpage>-<lpage>e1844</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2214-109X(22)00432-6</pub-id><?supplied-pmid 36400089?><pub-id pub-id-type="pmid">36400089</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kulick</surname><given-names>ER</given-names></string-name>, <string-name><surname>Canning</surname><given-names>M</given-names></string-name>, <string-name><surname>Parikh</surname><given-names>NS</given-names></string-name>, <string-name><surname>Elkind</surname><given-names>MSV</given-names></string-name>, <string-name><surname>Boehme</surname><given-names>AK</given-names></string-name></person-group>. <article-title>Seasonality of influenza-like-illness and acute cardiovascular events are related regardless of vaccine effectiveness</article-title>. <source>J Am Heart Assoc</source>. <year>2020</year>;<volume>9</volume>(<issue>20</issue>):<elocation-id>e016213</elocation-id>. doi:<pub-id pub-id-type="doi">10.1161/JAHA.120.016213</pub-id><?supplied-pmid 33028143?><pub-id pub-id-type="pmid">33028143</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ma</surname><given-names>P</given-names></string-name>, <string-name><surname>Tang</surname><given-names>X</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Influenza A and B outbreaks differed in their associations with climate conditions in Shenzhen, China</article-title>. <source>Int J Biometeorol</source>. <year>2022</year>;<volume>66</volume>(<issue>1</issue>):<fpage>163</fpage>-<lpage>173</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00484-021-02204-y</pub-id><?supplied-pmid 34693474?><pub-id pub-id-type="pmid">34693474</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Deyle</surname><given-names>ER</given-names></string-name>, <string-name><surname>Maher</surname><given-names>MC</given-names></string-name>, <string-name><surname>Hernandez</surname><given-names>RD</given-names></string-name>, <string-name><surname>Basu</surname><given-names>S</given-names></string-name>, <string-name><surname>Sugihara</surname><given-names>G</given-names></string-name></person-group>. <article-title>Global environmental drivers of influenza</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2016</year>;<volume>113</volume>(<issue>46</issue>):<fpage>13081</fpage>-<lpage>13086</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1607747113</pub-id><?supplied-pmid 27799563?><pub-id pub-id-type="pmid">27799563</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Serman</surname><given-names>E</given-names></string-name>, <string-name><surname>Thrastarson</surname><given-names>HT</given-names></string-name>, <string-name><surname>Franklin</surname><given-names>M</given-names></string-name>, <string-name><surname>Teixeira</surname><given-names>J</given-names></string-name></person-group>. <article-title>Spatial variation in humidity and the onset of seasonal influenza across the contiguous United States</article-title>. <source>Geohealth</source>. <year>2022</year>;<volume>6</volume>(<issue>2</issue>):<elocation-id>GH000469</elocation-id>. doi:<pub-id pub-id-type="doi">10.1029/2021GH000469</pub-id><?supplied-pmid 35136850?><pub-id pub-id-type="pmid">35136850</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ali</surname><given-names>ST</given-names></string-name>, <string-name><surname>Cowling</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Wong</surname><given-names>JY</given-names></string-name>, <etal/></person-group>. <article-title>Influenza seasonality and its environmental driving factors in mainland China and Hong Kong</article-title>. <source>Sci Total Environ</source>. <year>2022</year>;<volume>818</volume>:<elocation-id>151724</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.scitotenv.2021.151724</pub-id><?supplied-pmid 34800462?><pub-id pub-id-type="pmid">34800462</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Mohammad</surname><given-names>KN</given-names></string-name>, <string-name><surname>Chan</surname><given-names>EYY</given-names></string-name>, <string-name><surname>Wong</surname><given-names>MCS</given-names></string-name>, <string-name><surname>Goggins</surname><given-names>WB</given-names></string-name>, <string-name><surname>Chong</surname><given-names>KC</given-names></string-name></person-group>. <article-title>Ambient temperature, seasonal influenza and risk of cardiovascular disease in a subtropical area in Southern China</article-title>. <source>Environ Res</source>. <year>2020</year>;<volume>186</volume>:<elocation-id>109546</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.envres.2020.109546</pub-id><?supplied-pmid 32334173?><pub-id pub-id-type="pmid">32334173</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230908r30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Mohammad</surname><given-names>MA</given-names></string-name>, <string-name><surname>Tham</surname><given-names>J</given-names></string-name>, <string-name><surname>Koul</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Association of acute myocardial infarction with influenza: a nationwide observational study</article-title>. <source>PLoS One</source>. <year>2020</year>;<volume>15</volume>(<issue>8</issue>):<elocation-id>e0236866</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0236866</pub-id><?supplied-pmid 32760080?><pub-id pub-id-type="pmid">32760080</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <notes notes-type="supplementary-material" id="note-ZOI230908-1">
              <supplementary-material id="note-ZOI230908-1-s" position="float" content-type="local-data">
                <label>Supplement 1.</label>
                <caption>
                  <p>
Trial Protocol
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2331284-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 2.</label>
                <caption>
                  <p><bold>eTable.</bold> Association of Weekly Odds of Primary and Secondary Outcomes With Influenza-Like Illness Activity by Time</p>
                </caption>
                <media xlink:href="jamanetwopen-e2331284-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 3.</label>
                <caption>
                  <p>
Data Sharing Statement
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2331284-s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </notes>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
